{
    "id": "280b9843-9353-465b-9b94-c0d67b1e6fd6",
    "indications": {
        "text": "tzield indicated delay onset stage 3 type 1 diabetes adults pediatric patients 8 years age older stage 2 type 1 diabetes [ ( 2.1 ) ] .",
        "doid_entities": [
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "confirm stage 2 t1d documenting least two positive pancreatic islet autoantibodies dysglycemia without overt hyperglycemia using oral glucose tolerance test ( ogtt ) alternative method appropriate ogtt available ( 2.1 ) . patients meet criteria diagnosis stage 2 type 1 diabetes , ensure history patient suggest type 2 diabetes ( 2.1 ) . prior initiating tzield , obtain complete blood count liver enzyme tests . tzield recommended patients certain laboratory abnormalities ( 2.2 ) . must dilute tzield 0.9 % sodium chloride injection , usp . full prescribing information detailed preparation instructions ( 2.3 , 2.4 , 2.5 ) . premedicate : ( 1 ) nonsteroidal anti-inflammatory ( nsaid ) acetaminophen , ( 2 ) antihistamine , and/or ( 3 ) antiemetic tzield dose least first 5 days 14-day treatment course ( 2.3 ) . administer tzield intravenous infusion ( minimum 30 minutes ) daily 14 days . full prescribing information dosing schedule ( 2.4 ) .",
        "doid_entities": [
            {
                "text": "hyperglycemia (DOID:4195)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4195"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            },
            {
                "text": "type 2 diabetes (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "tzield ( teplizumab-mzwv ) injection clear colorless solution ( 2 mg/2 ml ( 1 mg/ml ) ) supplied single-dose vial follows : carton contents ndc 1 single dose vial ndc 73650-316-01 10 single dose vials ndc 73650-316-10 14 single dose vials ndc 73650-316-14 refrigerate tzield vials 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) original carton protect light . store upright . freeze shake vials . used immediately , store diluted solution room temperature [ 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) ] complete infusion within 4 hours start preparation . discard diluted solution administered within 4 hours preparation [ ( 2.5 ) ] .",
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "TEPLIZUMAB",
            "code": "S4M959U2IJ",
            "drugbank_id": "https://go.drugbank.com/drugs/DB06606"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, DODECAHYDRATE",
            "code": "E1W4N241FO",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE",
            "code": "5QWK665956",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "organization": "Provention Bio, Inc.",
    "name": "TZIELD",
    "effectiveTime": "20250506",
    "indications_original": "TZIELD is indicated to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients 8 years of age and older with Stage 2 type 1 diabetes [see Dosage and Administration (2.1)].",
    "contraindications_original": "Confirm Stage 2 T1D by documenting at least two positive pancreatic islet autoantibodies in those who have dysglycemia without overt hyperglycemia using an oral glucose tolerance test (OGTT) or alternative method if appropriate and OGTT is not available ( 2.1 ). In patients who meet criteria for a diagnosis of Stage 2 type 1 diabetes, ensure the clinical history of the patient does not suggest type 2 diabetes ( 2.1 ). Prior to initiating TZIELD, obtain a complete blood count and liver enzyme tests. Use of TZIELD is not recommended in patients with certain laboratory abnormalities ( 2.2 ). Must dilute TZIELD in 0.9% Sodium Chloride Injection, USP. See full prescribing information for detailed preparation and administration instructions ( 2.3 , 2.4 , 2.5 ). Premedicate with: (1) a nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen, (2) an antihistamine, and/or (3) an antiemetic before each TZIELD dose for at least the first 5 days of the 14-day treatment course ( 2.3 ). Administer TZIELD by intravenous infusion (over a minimum of 30 minutes) once daily for 14 days. See full prescribing information for the dosing schedule ( 2.4 ).",
    "warningsAndPrecautions_original": "TZIELD (teplizumab-mzwv) injection is a clear and colorless solution (2 mg/2 mL (1 mg/mL)) supplied in a single-dose vial as follows:\n                  \n                     \n                     \n                     \n                        \n                           Carton Contents\n                           NDC\n                        \n                     \n                     \n                        \n                           1 single dose vial\n                           NDC 73650-316-01\n                        \n                        \n                           10 single dose vials\n                           NDC 73650-316-10\n                        \n                        \n                           14 single dose vials\n                           NDC 73650-316-14\n                        \n                     \n                  \n                  Refrigerate TZIELD vials at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) in the original carton to protect from light. Store upright. Do not freeze or shake the vials.\n                  If not used immediately, store the diluted solution at room temperature [15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F)] and complete infusion within 4 hours of the start of preparation. Discard the diluted solution if not administered within 4 hours of preparation [see Dosage and Administration (2.5)].",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "TZIELD",
            "drugbank_id": "https://go.drugbank.com/drugs/DB06606"
        }
    ]
}